sanofi glp-1 2025’s Breakthrough Obesity Treatments: Top Companies & Innovations and intra DCA and Sanofi win iF

E.OlivosD

Menopause weight gain is real, it is biological, and it is not a failure of willpower

This relationship is also reflected in its impact on muscle mass

Wegovy (semaglutide) and Zepbound (tirzepatide) are approved for weight loss and obesity management

This supportive environment can overlap with other weight-loss programs, such as self-help groups and commercial programs, enhancing the overall effectiveness of the therapy

PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after first month), which analyzes 150+ genetic insights across 14 metabolic pathways, including key variants in the GLP1R gene (rs6923761), GIPR pathway (rs1800437), FTO obesity risk locus (rs9939609), and MC4R appetite regulation (rs17782313)